Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 735
Filtrar
1.
Buenos Aires; IECS; 2 dic. 2020.
No convencional en Español | LILACS, BRISA/RedTESA | ID: biblio-1140939

RESUMEN

INTRODUCCIÓN: La pandemia de COVID-19 está afectando a miles de millones de personas en todo el mundo. Hasta la actualidad a nivel mundial se registraron ya más de 58 millones de casos y 1 millón 390 mil muertes y en nuestro país ya se han acumulado más de 1,3 millones de casos y más de 37 mil muertes.1 El patógeno causante, el coronavirus del síndrome respiratorio agudo severo 2 (SARS-CoV-2 o SC2), pertenece a una familia de betacoronavirus que son virus de ARN de cadena única envueltos y que infectan a mamíferos. Existen variaciones considerables en los diferentes países en cuanto a la epidemiología de COVID-19, sus métodos de evaluación y rastreo, las estrategias terapéuticas y de gestión de los pacientes y de las herramientas preventivas. La tasa de letalidad de COVID-19 muestra una fuerte correlación con la edad, la presencia de comorbilidades y el status inmunológico de los pacientes. Los ancianos y las personas con comorbilidades como hipertensión, dislipemias, antecedentes de cardiopatía isquémica, enfermedad pulmonar obstructiva crónica, enfermedad hepática o renal crónica, o pacientes inmunocomprometidos es más probable que presenten formas graves de la enfermedad y tasas de mortalidad más elevadas. Hasta este el momento no existe tratamiento curativo para COVID-19 y los esfuerzos se concentran en frenar la propagación de la enfermedad y de esta forma mitigar el daño. La inmunidad de rebaño ha sido considerada como una forma efectiva de frenar la propagación de la enfermedad. La inmunidad de rebaño puede lograrse por la infección natural o por la vacunación. Sin embargo, la proporción de la población que debe ser inmunizada para lograr la inmunidad de rebaño varía de uma enfermedad a otra. Se han realizado diversas estimaciones acerca del nivel de inmunidad que debería tener una población para detener el avance de la pandemia de COVID-19 en un 70% de la población, lo cual representan más de 30 millones de personas en Argentina. De todas maneras, aún existe incertidumbre acerca de la duración de la inmunidad que confiere la infección por SC2 y han sido reportados algunos casos de reinfecciones.4 Además, se han notificado mutaciones del SC2 y la creciente población de los pacientes recuperados de COVID-19 podrían no contribuir a la inmunidadefectiva de rebaño si las oleadas subsiguientes de la pandemia se producen por variantes del SC2 frente a las cuales no se desarrollaron anticuerpos neutralizantes. La infección generalizada por el SC2 podría dar lugar a complicaciones graves y a altas tasas de mortalidad, especialmente entre los ancianos y las personas con enfermedades crónicas y también podría suponer una grave carga para el sistema de atención de la salud y, a su vez, causar grandes trastornos económicos. Por lo tanto, el desarrollo de vacunas seguras y eficaces es la mejor respuesta frente a la pandemia. Idealmente, el desarrollo de una vacuna optimizada capaz de brindar protección contra múltiples cepas de betacoronavirus sería más eficiente, en previsión de futuros brotes que podrían surgir de diferentes tipos de cepas de coronavirus. OBJETIVOS: Describir las características que debería tener la vacunación para COVID-19, las diferentes tecnologias utilizadas en su desarrollo, así como resumir información de aquellas vacunas que se encuentren em fases avanzadas de investigación clínica. Además, presentar información preliminar acerca de eficácia y seguridad de estas vacunas. MÉTODOS: Se realizó una búsqueda en las principales bases de datos bibliográficas de artículos revisados por pares, en buscadores de artículos científicos que se encuentran en proceso de revisión por pares, em buscadores genéricos de internet y en plataformas de seguimiento del desarrollo de vacunas de instituciones académicas. CONCLUSIÓN: En el presente documento se recopila información proveniente de artículos científicos revisados por pares, artículos no revisados por pares, informes de diferentes plataformas de rastreo del desarrollo de vacunas y comunicaciones oficiales por parte de las empresas o institutos de investigación que lideran los ensayos de las potenciales vacunas en estudio.


Asunto(s)
Humanos , Infecciones por Coronavirus/prevención & control , Evaluación de la Tecnología Biomédica , Vacunas/provisión & distribución , Resultado del Tratamiento , Análisis Costo-Beneficio
2.
Goiania; SES-GO; 11 dez. 2020. 1-5 p. tab.
No convencional en Portugués | LILACS, Coleciona SUS, CONASS, SES-GO | ID: biblio-1145519

RESUMEN

De acordo com a Organização Mundial de Saúde (OMS), até o dia 08 de dezembro de 2020, foram notificados 67.210.778 casos de COVID-19 e 1.540.777 mortes pela doença (WHO Coronavirus Disease / COVID-19 / Dashboard). Países do mundo inteiro anseiam pelo desenvolvimento de vacinas com comprovada eficácia e segurança, a fim de conter o avanço da pandemia. Algumas empresas farmacêuticas e universidades estão mais avançadas nessa corrida no campo da pesquisa clínica. Atualmente 51 vacinas estão sendo pesquisadas em ensaios clínicos com humanos, sendo que 13 delas estão na Fase 3 de estudos, ou seja, prestes a serem comercializadas (OMS, 2020). Os estudos de Fase 3 envolvem a realização de ensaios clínicos randomizados, placebo controlados, multicêntricos com milhares de voluntários que tem como objetivo principal determinar a relação risco/benefício a curto e longo prazo, reações adversas e o valor terapêutico do produto (SBPPC, 2020).


According to the World Health Organization (WHO), as of December 8, 2020, 67,210,778 cases of COVID-19 and 1,540,777 deaths from the disease (WHO Coronavirus Disease / COVID-19 / Dashboard) were reported. Countries around the world yearn for the development of vaccines with proven efficacy and safety in order to contain the advance of the pandemic. Some pharmaceutical companies and universities are more advanced in this race in the field of clinical research. Currently 51 vaccines are being researched in clinical trials with humans, 13 of which are in Phase 3 of studies, that is, about to be commercialized (WHO, 2020). Phase 3 studies involve randomized, placebo-controlled, multicenter trials with thousands of volunteers whose main objective is to determine the short- and long-term risk/benefit ratio, adverse reactions and therapeutic value of the product (SBPPC, 2020).


Asunto(s)
Humanos , Vacunas/provisión & distribución , Infecciones por Coronavirus/prevención & control
5.
ABCS health sci ; 45: [1-6], 02 jun 2020. tab
Artículo en Inglés | LILACS | ID: biblio-1097547

RESUMEN

INTRODUCTION: Immunobiologicals are of great importance for the prevention and eradication of diseases. However, the lack of maintenance of the cold chain generates several problems related to losses of these substances, burdening an important amount of public resources. OBJECTIVE: To analyze vaccine losses in a Health Region (Região Ampliada de Saúde Oeste) of Minas Gerais State in Brazil. METHODS: This is a descriptive study, based on secondary data obtained through forms used by the regional health agency (Superintendência Regional de Saúde, SRS), to register losses of immunobiologicals due to temperature changes. Forms from February 2016 through January 2018 were analyzed. The data was organized and validated by double typing. RESULTS: Vaccine losses were caused by lack of electrical energy (40.83%), followed by equipment failure (36.67%), and professional error (10%). As a consequence, 17,229 bottles of vaccines (65.78%) were discarded, corresponding to 111,145 doses. The financial loss was R$ 604,340.31. CONCLUSION: Losses of vaccines due to temperature changes were relevant in the studied region, damaging the budget for the local health network. Therefore, it is suggested that measures to minimize these losses should be adopted.


INTRODUÇÃO: Os imunobiológicos são de grande importância para a prevenção e erradicação de doenças. Entretanto, a falta de manutenção da Rede de Frio gera diversos problemas relacionados a perdas dessas substâncias, onerando uma importante quantia de recursos públicos. OBJETIVO: Analisar as perdas vacinais da Região Ampliada de Saúde Oeste de Minas Gerais. MÉTODOS: Trata-se de um estudo descritivo, com base em dados secundários obtidos através de formulários utilizados pela Superintendência Regional de Saúde (SRS), para avaliação de perdas de imunobiológicos por alteração de temperatura. Foram analisados os formulários de fevereiro de 2016 até janeiro de 2018. Os dados foram organizados e validados por dupla digitação, e a análise foi feita descritivamente. RESULTADOS: Os resultados mostraram que dos motivos das ocorrências 40,83% foram por falta de energia elétrica, seguida de falha no equipamento (36,67%), e erro do profissional (10%). Foram inutilizados 17229 frascos de vacinas (65,78%), sendo 111.145 doses, com uma perda financeira de R$ 604.340,31. CONCLUSÃO: Identificou-se que as perdas físicas por alteração de temperatura de vacinas na região estudada foram relevantes, gerando prejuízos para o orçamento do SUS. Dessa forma sugere-se a adoção de condutas para minimizar estas perdas.


Asunto(s)
Refrigeración , Temperatura , Vacunas/provisión & distribución
6.
Emerg Top Life Sci ; 4(2): 241-245, 2020 09 08.
Artículo en Inglés | MEDLINE | ID: mdl-32463081

RESUMEN

Skepticism and misinformation relating to vaccines is not new. The benefits of all our present routinely used vaccines outweigh any risks. In relatively recent times there has been a 'war on science' and relating to this, is the present antivaccine movement. Today, social media is a major contributor to vaccine misinformation. A recent Gallup poll noted that public support for vaccines today is significantly lower than it was in 2001. Social scientists have presented the problem of the antivaccine movement quite well; but mechanisms for addressing it are far from clear. We suggest that physicians and other health care workers should not use social media for vaccine messages. A long-term approach would be to introduce science/epidemiological education in grade school and high school as well as in college.


Asunto(s)
Movimiento Anti-Vacunación , Sociología , Vacunación/tendencias , Comunicación , Programas de Gobierno , Personal de Salud , Humanos , Salud Pública , Medios de Comunicación Sociales , Vacunas/efectos adversos , Vacunas/provisión & distribución
7.
Hastings Cent Rep ; 50(3): 46-49, 2020 05.
Artículo en Inglés | MEDLINE | ID: mdl-32468631

RESUMEN

The Covid-19 pandemic needs to be considered from two perspectives simultaneously. First, there are questions about which policies are most effective and fair in the here and now, as the pandemic unfolds. These polices concern, for example, who should receive priority in being tested, how to implement contact tracing, or how to decide who should get ventilators or vaccines when not all can. Second, it is imperative to anticipate the medium- and longer-term consequences that these policies have. The case of vaccine rationing is particularly instructive. Ethical, epidemiological, and economic reasons demand that rationing approaches give priority to groups who have been structurally and historically disadvantaged, even if this means that overall life years gained may be lower.


Asunto(s)
Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/prevención & control , Asignación de Recursos para la Atención de Salud/ética , Pandemias/prevención & control , Neumonía Viral/epidemiología , Neumonía Viral/prevención & control , Vacunas/provisión & distribución , Factores de Edad , Betacoronavirus , Control de Enfermedades Transmisibles/organización & administración , Comorbilidad , Trazado de Contacto/ética , Trazado de Contacto/métodos , Grupos de Población Continentales , Infecciones por Coronavirus/etnología , Estado de Salud , Disparidades en el Estado de Salud , Humanos , Neumonía Viral/etnología , Justicia Social , Factores Socioeconómicos , Ventiladores Mecánicos/provisión & distribución
8.
Pan Afr Med J ; 35(Suppl 1): 11, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32373262

RESUMEN

Introduction: Poor data quality and use have been identified as key challenges that negatively impact immunization programs in low- and middle-income countries (LMICs). In addition, many LMICs have a shortage of health personnel, and staff available have demanding workloads across several health programs. In order to address these challenges, the Better Immunization Data (BID) Initiative introduced a comprehensive suite of interventions, including an electronic immunization registry aimed at improving the quality, reliability, and use of immunization data in Arusha Region, Tanzania, and Southern Province of Zambia. The objective of this study was to assess the incremental costs of implementing the BID interventions in immunization programs in these two countries. Methods: We conducted a micro-costing study to estimate the economic costs of service delivery and logistics for the immunization programs with and without the BID interventions in a sample of health facilities and district program offices in each country. Structured questionnaires were used to interview immunization program staff at baseline and post-intervention to assess annual resource utilization and costs. Cost outcomes were reported as annual cost per facility, cost per district and changes in resource costs due to the BID interventions (i.e., costs associated with health worker time, start-up costs, etc.). Sub-group analyses were conducted by health facility to assess variation in costs by volume served and location (rural versus urban). One-way sensitivity analyses were conducted to identify influential parameters. Costs were reported in 2017 US dollars. Results: In Tanzania, the average annual reduction in resource costs was estimated at US$10,236 (95% confidence interval: $7,606-$14,123) per health facility, while the average annual reduction in resource costs per district was estimated at $6,542. In Zambia, reductions in resource costs were modest at an estimated annual average of $628 (95% confidence interval: $209-$1,467) per health facility and $236 per district. Resource cost reductions were mainly attributable to reductions in time required for immunization service delivery and reporting. One-way sensitivity analyses identified key cost drivers, all related to reductions in health worker time. Conclusion: The introduction of electronic immunization registries and stock management systems through the BID Initiative was estimated to result in potential time savings in both countries. Health worker time was the area most impacted by the interventions, suggesting that time savings gained could be utilized for patient care. Information generated through this work provides evidence to inform stakeholder decision-making for scale-up of the BID interventions in Tanzania and Zambia and to inform other Low-to-Middle-Income Countries (LMICs) interested in similar interventions.


Asunto(s)
Registros Electrónicos de Salud , Vacunación Masiva/economía , Vacunación Masiva/organización & administración , Sistema de Registros , Reserva Estratégica/economía , Reserva Estratégica/organización & administración , Vacunas , Niño , Ahorro de Costo/métodos , Análisis Costo-Beneficio , Exactitud de los Datos , Prestación de Atención de Salud/economía , Prestación de Atención de Salud/organización & administración , Prestación de Atención de Salud/estadística & datos numéricos , Registros Electrónicos de Salud/economía , Registros Electrónicos de Salud/organización & administración , Costos de la Atención en Salud , Humanos , Programas de Inmunización/economía , Programas de Inmunización/métodos , Programas de Inmunización/organización & administración , Programas de Inmunización/estadística & datos numéricos , Vacunación Masiva/métodos , Vacunación Masiva/estadística & datos numéricos , Vigilancia de la Población/métodos , Reserva Estratégica/estadística & datos numéricos , Tanzanía/epidemiología , Cobertura de Vacunación/economía , Cobertura de Vacunación/organización & administración , Cobertura de Vacunación/estadística & datos numéricos , Vacunas/economía , Vacunas/provisión & distribución , Zambia/epidemiología
9.
Brasília; s.n; 22 maio 2020.
No convencional en Portugués | LILACS, BRISA/RedTESA, PIE | ID: biblio-1097386

RESUMEN

O Informe Diário de Evidências é uma produção do Ministério da Saúde que tem como objetivo acompanhar diariamente as publicações científicas sobre tratamento farmacológico e vacinas para a COVID-19. Dessa forma, são realizadas buscas estruturadas em bases de dados biomédicas, referente ao dia anterior desse informe. Não são incluídos estudos pré-clínicos (in vitro, in vivo, in silico). A frequência dos estudos é demonstrada de acordo com a sua classificação metodológica (revisões sistemáticas, ensaios clínicos randomizados, coortes, entre outros). Para cada estudo é apresentado um resumo com avaliação da qualidade metodológica. Essa avaliação tem por finalidade identificar o grau de certeza/confiança ou o risco de viés de cada estudo. Para tal, são utilizadas ferramentas já validadas e consagradas na literatura científica, na área de saúde baseada em evidências. Cabe ressaltar que o documento tem caráter informativo e não representa uma recomendação oficial do Ministério da Saúde sobre a temática. Foram encontrados 21 artigos e 13 protocolos.


Asunto(s)
Neumonía Viral/tratamiento farmacológico , Infecciones por Coronavirus/tratamiento farmacológico , Progresión de la Enfermedad , Betacoronavirus/efectos de los fármacos , Piperacilina/uso terapéutico , Evaluación de la Tecnología Biomédica , Vacunas/provisión & distribución , Cloroquina/uso terapéutico , Activador de Tejido Plasminógeno/uso terapéutico , Corticoesteroides/uso terapéutico , Ritonavir/uso terapéutico , Combinación de Medicamentos , Lopinavir/uso terapéutico , Clorhidrato de Fingolimod/uso terapéutico , Tazobactam/uso terapéutico , Hidroxicloroquina/uso terapéutico , Insulina/uso terapéutico , Anticoagulantes/uso terapéutico
12.
Int Health ; 12(3): 170-176, 2020 05 01.
Artículo en Inglés | MEDLINE | ID: mdl-31647527

RESUMEN

BACKGROUND: Universal access to vaccines is crucial in protecting the population from deadly diseases. This study presents the prevalence of vaccine stockouts in Nigeria and examines the correlation between the vaccine stockouts and vaccine take-up. METHODS: We use the unique administrative data of monthly vaccine stockouts at each health facility in Nigeria. To evaluate the correlation between the stockouts and the vaccine take-up, the administrative data were merged with the Nigeria Demographic and Health Survey conducted in 2013. We used logistic regression for the correlational study. RESULTS: The prevalence of vaccine stockouts in Nigeria is high: 82.7% between 2012 and 2013. We find a negative correlation between vaccine stockouts and vaccine take-up. However, we observe the differential correlational pattern depending on the regional vaccine coverage, which we consider as the proxy of the level of demand for vaccines. CONCLUSIONS: We find that, while vaccine stockouts are correlated with the low vaccine take-up on average, this negative correlation between stockouts and vaccination rate is observed only in regions with low demand for vaccines. Reducing vaccine stockouts in regions with the low vaccination coverage might be an effective way to increase the overall vaccination rate.


Asunto(s)
Programas de Inmunización/estadística & datos numéricos , Cobertura de Vacunación/estadística & datos numéricos , Vacunas/provisión & distribución , Adulto , Preescolar , Encuestas Epidemiológicas , Humanos , Lactante , Modelos Logísticos , Nigeria , Prevalencia , Vacunación/estadística & datos numéricos
13.
Bull World Health Organ ; 97(12): 797-798, 2019 Dec 01.
Artículo en Inglés | MEDLINE | ID: mdl-31819287

RESUMEN

Ahd Hamidi talks to Gary Humphreys about technology transfer and the implications of new vaccine production methods for local production.


Asunto(s)
Industria Farmacéutica/organización & administración , Vacunas/provisión & distribución , Industria Farmacéutica/normas , Salud Global , Humanos
15.
Glob Health Sci Pract ; 7(4): 585-597, 2019 12 23.
Artículo en Inglés | MEDLINE | ID: mdl-31852740

RESUMEN

BACKGROUND: Global vaccination coverage rates have remained around 85% for the past several years. Increasing immunization coverage rates requires an effective cold chain to maintain vaccine potency. Remote temperature monitoring (RTM) technology for vaccine refrigerators has shown promise for improving the ability of supply systems to maintain optimal temperature conditions to ensure potent vaccines reach the end users. METHODS: A pilot study of RTM technology and data use teams was implemented in 36 study sites in Kenya. Data were collected at baseline and endline points over a 3-month baseline and 7-month implementation period. Data included 44 qualitative interviews, process logs, meeting minutes from data use team meetings, and quantitative temperature and power data from the RTM devices. RESULTS: The ability of cold chain equipment to maintain World Health Organization-recommended temperatures in study sites improved markedly between the baseline and implementation periods, resulting in an improvement in total time spent in the correct range from 83.9% in the baseline period to 90.9% in the intervention period and an improvement in time spent in the too cold range from 6.5% to 1.5%. Friedman tests revealed that differences in time spent in the correct range and time spent in the too cold range during the course of the study were statistically significant (P<.001 and P=.04, respectively). Qualitative and quantitative data suggest that this improvement was due to a combination of improved responsiveness to temperature excursions at the facility level, resulting from SMS alarms for temperature excursion periods, and improved ability at the management level to recognize and address recurring problems. CONCLUSION: The combination of using RTM technology with a structured data review process by a management team is a promising approach for improving cold chain outcomes. Future research examining the added value of each of the technological and behavioral components separately is needed.


Asunto(s)
Almacenaje de Medicamentos/métodos , Tecnología de Sensores Remotos , Temperatura , Vacunas/provisión & distribución , Estabilidad de Medicamentos , Humanos , Kenia , Proyectos Piloto
16.
J Med Internet Res ; 21(11): e14007, 2019 11 04.
Artículo en Inglés | MEDLINE | ID: mdl-31682571

RESUMEN

BACKGROUND: Tools used to appraise the credibility of health information are time-consuming to apply and require context-specific expertise, limiting their use for quickly identifying and mitigating the spread of misinformation as it emerges. OBJECTIVE: The aim of this study was to estimate the proportion of vaccine-related Twitter posts linked to Web pages of low credibility and measure the potential reach of those posts. METHODS: Sampling from 143,003 unique vaccine-related Web pages shared on Twitter between January 2017 and March 2018, we used a 7-point checklist adapted from validated tools and guidelines to manually appraise the credibility of 474 Web pages. These were used to train several classifiers (random forests, support vector machines, and recurrent neural networks) using the text from a Web page to predict whether the information satisfies each of the 7 criteria. Estimating the credibility of all other Web pages, we used the follower network to estimate potential exposures relative to a credibility score defined by the 7-point checklist. RESULTS: The best-performing classifiers were able to distinguish between low, medium, and high credibility with an accuracy of 78% and labeled low-credibility Web pages with a precision of over 96%. Across the set of unique Web pages, 11.86% (16,961 of 143,003) were estimated as low credibility and they generated 9.34% (1.64 billion of 17.6 billion) of potential exposures. The 100 most popular links to low credibility Web pages were each potentially seen by an estimated 2 million to 80 million Twitter users globally. CONCLUSIONS: The results indicate that although a small minority of low-credibility Web pages reach a large audience, low-credibility Web pages tend to reach fewer users than other Web pages overall and are more commonly shared within certain subpopulations. An automatic credibility appraisal tool may be useful for finding communities of users at higher risk of exposure to low-credibility vaccine communications.


Asunto(s)
Aprendizaje Automático/normas , Medios de Comunicación Sociales/normas , Vacunas/provisión & distribución , Monitoreo Epidemiológico , Humanos , Estudios Retrospectivos , Red Social
17.
Nature ; 575(7781): 119-129, 2019 11.
Artículo en Inglés | MEDLINE | ID: mdl-31695203

RESUMEN

Vaccination against infectious diseases has changed the future of the human species, saving millions of lives every year, both children and adults, and providing major benefits to society as a whole. Here we show, however, that national and sub-national coverage of vaccination varies greatly and major unmet needs persist. Although scientific progress opens exciting perspectives in terms of new vaccines, the pathway from discovery to sustainable implementation can be long and difficult, from the financing, development and licensing to programme implementation and public acceptance. Immunization is one of the best investments in health and should remain a priority for research, industry, public health and society.


Asunto(s)
Desarrollo de Medicamentos/economía , Vacunación/tendencias , Vacunas/inmunología , Vacunas/provisión & distribución , Animales , Humanos , Mortalidad , Filipinas/epidemiología , Cambio Social , Vacunación/economía , Vacunas/economía
18.
Am J Manag Care ; 25(11): e334-e341, 2019 11 01.
Artículo en Inglés | MEDLINE | ID: mdl-31747238

RESUMEN

OBJECTIVES: To identify the most important reasons underlying decisions to stock or not stock adult vaccines. STUDY DESIGN: US physicians, nurses, pharmacists, and administrators of internal medicine, family medicine, obstetrics/gynecology, and multispecialty practices who were involved in vaccine stocking decisions (N = 125) completed a best-worst scaling survey online between February and April 2018. METHODS: Sixteen potential factors influencing stocking decisions were developed based on key informant interviews and focus groups. Respondents selected factors that were most and least important in vaccine stocking decisions. Relative importance scores for the best-worst scaling factors were calculated. Survey respondents described which vaccines their practice stocks and reasons for not stocking specific vaccines. Subgroup analyses were performed based on the respondent's involvement in vaccine decision making, role in the organization, specialty, and affiliation status, as well as practice characteristics such as practice size, insurance mix, and patient age mix. RESULTS: Relative importance scores for stocking vaccines were highest for "cost of purchasing vaccine stock," "expense of maintaining vaccine inventory," and "lack of adequate reimbursement for vaccine acquisition and administration." Most respondents (97%) stocked influenza vaccines, but stocking rates of other vaccines varied from 39% (meningococcal B) to 83% (tetanus-diphtheria-pertussis). Best-worst scaling results were consistent across respondent subgroups, although the range of vaccine types stocked differed by practice type. CONCLUSIONS: Economic factors associated with the purchase and maintenance of vaccine inventory and inadequate reimbursement for vaccination services were the most important to decision makers when considering whether to stock or not stock vaccines for adults.


Asunto(s)
Actitud del Personal de Salud , Toma de Decisiones , Almacenaje de Medicamentos/economía , Vacunas/economía , Vacunas/provisión & distribución , Adulto , Femenino , Grupos Focales , Humanos , Masculino , Encuestas y Cuestionarios , Estados Unidos
19.
Vaccine ; 37(43): 6268-6270, 2019 10 08.
Artículo en Inglés | MEDLINE | ID: mdl-31526621

RESUMEN

Immunization Information Systems (IIS) are computerized population-based systems with individual-level vaccination-related information used to help ensure protection from vaccine preventable diseases. The Chinese Center for Diseases Control and Prevention (China CDC) conducted a survey of the 32 mainland China provincial CDCs to determine IIS coverage and implementation of key functions: individual vaccination records, vaccine management, cold-chain management, and school entry vaccination status verification. Twenty-seven IISs collectively managed 252 million immunization records, 43.8% for children under 6 years; 20 could exchange records with other IISs. The within-province duplicate-record rate varied from 0.3% to 4.0%, but compared with National Statistical Bureau's census estimates, 138.0% of births from 2012 to 2017 were represented in the IISs, implying significant across-province record duplication. China CDC should consider developing a national-level IIS center for data exchange and analysis.


Asunto(s)
Sistemas de Información en Salud/organización & administración , Programas de Inmunización/estadística & datos numéricos , Informática Médica/estadística & datos numéricos , Cobertura de Vacunación/estadística & datos numéricos , Niño , China , Humanos , Vacunas/administración & dosificación , Vacunas/provisión & distribución
20.
Cell ; 179(1): 13-17, 2019 Sep 19.
Artículo en Inglés | MEDLINE | ID: mdl-31519310

RESUMEN

This year's Lasker-Bloomberg Public Service Award goes to GAVI, the Vaccine Alliance, for providing sustained access to childhood vaccines around the globe, saving millions of lives, and highlighting the power of immunization to prevent disease.


Asunto(s)
Cooperación Internacional , Vacunación/economía , Vacunación/historia , Vacunas/historia , Vacunas/provisión & distribución , Niño , Salud Global , Historia del Siglo XVII , Historia del Siglo XVIII , Historia del Siglo XIX , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Programas de Inmunización , Inversiones en Salud , Pobreza , Medicina Preventiva/métodos , Vacunas/economía
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA